Abstract 142P
Background
Pancreatic cancer (PC) remains a major health concern due to its dismal prognosis and high mortality rates. Hypoxia-inducible factor 1-alpha (HIF-1α) is implicated in promoting tumor growth, angiogenesis, and metabolic changes under hypoxic conditions. However, an all-inclusive understanding of HIF-1α's precise role and clinical impact on PC is yet to be ascertained. This study aims to study the influence of HIF-1α on PC. Specifically, the goal is to assess differences in overall survival (OS) and OS in the context of metastasis between PC patients with high and low expression of HIF-1α.
Methods
We comprehensively searched PubMed, Embase, and the Cochrane Library databases for relevant research articles published until December 2022. Studies eligible for inclusion compared clinical outcomes in PC patients expressing high and low levels of HIF-1α. Primary outcomes of interest were OS and OS in patients with metastasis, computed using the hazard ratio (HR). The R software (version 4.0.3) with metafor and meta packages was used for all statistical analyses, utilizing random-effects models.
Results
Our meta-analysis encompassed 16 studies, representing a cohort of 1,080 PC patients, including 566 with high HIF-1α expression and 514 with low HIF-1α expression. The pooled HR for OS was 1.86 (95% CI: 1.64-2.12, P<0.01, I2=0%), indicating significantly lower survival rates among patients expressing high HIF-1α. More crucially, the pooled HR for OS in patients with metastasis was 2.09 (95% CI: 1.67-2.64, P<0.01, I2=0%), suggesting an even poorer survival outcome in metastatic PC patients with high HIF-1α expression.
Conclusions
Our findings highlight the considerable prognostic role of HIF-1α in PC, particularly elucidating its fundamental role in disease progression and prognosis, especially in the context of metastasis. These insights could stimulate the development of innovative therapeutic strategies that target HIF-1α, with potential implications for enhancing survival rates in PC patients. Further studies should validate these findings in larger, prospective cohorts and further investigate the specific mechanisms through which HIF-1α exacerbates PC progression, particularly in metastatic cases.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
169P - A real-world molecular pre-screening program in advanced breast cancer (ABC) at Institut Català d'Oncologia l'Hospitalet: Clinical practice study to assess treatment-decision choice based on molecular results
Presenter: David Lluís Garulo
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - KRAS status in patients with pancreatic ductal adenocarcinoma: A single-center study from 2020 to 2023
Presenter: Manukyan Mariam
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Benefit of next-generation sequencing for lung cancer patients in a limited-resource area
Presenter: Kijjakom Thanasombunsukh
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - Survival prediction using CT based radiomic features in patients of pancreatic cancer treated by chemotherapy followed by SBRT: A pilot study
Presenter: Divya Khosla
Session: Cocktail & Poster Display session
Resources:
Abstract
173P - Overcoming monocyte imbalance and T cell exhaustion in obesity-associated colorectal cancer liver metastasis
Presenter: Alyssa Cristea
Session: Cocktail & Poster Display session
Resources:
Abstract
174TiP - A pivotal clinical trial of a functional ex vivo organ culture assay for cancer precision medicine
Presenter: Sandra Hanks
Session: Cocktail & Poster Display session
Resources:
Abstract
177TiP - Myeloid-derived suppressor cells in the peripheral blood of patients with colorectal cancer: A trial in progress
Presenter: Hans Raskov
Session: Cocktail & Poster Display session
Resources:
Abstract